Financial Sense Advisors Inc. Buys New Holdings in Pfizer Inc. (NYSE:PFE)

Financial Sense Advisors Inc. purchased a new position in Pfizer Inc. (NYSE:PFE) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 22,855 shares of the biopharmaceutical company’s stock, valued at approximately $634,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Advisor OS LLC raised its holdings in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC boosted its holdings in shares of Pfizer by 3.9% during the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after purchasing an additional 371 shares during the period. Lantz Financial LLC grew its stake in shares of Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 381 shares during the last quarter. King Wealth Management Group lifted its holdings in Pfizer by 2.4% in the 4th quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 388 shares during the period. Finally, Advance Capital Management Inc. grew its position in shares of Pfizer by 4.0% in the 4th quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 391 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $27.70 on Thursday. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock has a market cap of $156.96 billion, a P/E ratio of -461.09, a P/E/G ratio of 1.09 and a beta of 0.69. The business’s 50 day moving average price is $27.96 and its 200-day moving average price is $27.71. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the business earned $1.23 earnings per share. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.06%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, June 26th. BMO Capital Markets restated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Morgan Stanley increased their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and an average target price of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.